Priority Research Papers:
Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy
Metrics: PDF 770 views | HTML 2690 views | ?
Sara Sandri1,*, Francesco De Sanctis1,*, Alessia Lamolinara2, Federico Boschi3, Ornella Poffe1, Rosalinda Trovato1, Alessandra Fiore1, Sara Sartori1, Andrea Sbarbati4, Attilio Bondanza5, Simone Cesaro6, Mauro Krampera7, Maria T. Scupoli7,8, Michael I. Nishimura9, Manuela Iezzi2, Silvia Sartoris1, Vincenzo Bronte1 and Stefano Ugel1
1 Department of Medicine, University of Verona, Section of Immunology, Verona, Italy
2 Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D’Annunzio University, Chieti-Pescara, Italy
3 Department of Computer Science, University of Verona, Verona, Italy
4 Department of Neurological and Movement Sciences, University of Verona, Verona, Italy
5 Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy
6 Department of Pediatric Haematology Oncology, University of Verona, Verona, Italy
7 Department of Medicine, University of Verona, Section of Haematology, Verona, Italy
8 University of Verona, Interdepartmental Laboratory for Medical Research (LURM), Verona, Italy
9 Department of Surgery, Loyola University Medical Center, Maywood, IL, United States
* These authors have contributed equally to this work
Stefano Ugel, email:
Keywords: acute myeloid leukaemia (AML), B-cell acute lymphoblastic leukaemia (B-ALL), telomerase (TERT), TCR-redirected T-cells, adoptive cell therapy (ACT)
Received: November 08, 2016 Accepted: May 12, 2017 Published: May 23, 2017
Telomerase (TERT) is a ribonucleoprotein enzyme that preserves the molecular organization at the ends of eukaryotic chromosomes. Since TERT deregulation is a common step in leukaemia, treatments targeting telomerase might be useful for the therapy of hematologic malignancies. Despite a large spectrum of potential drugs, their bench-to-bedside translation is quite limited, with only a therapeutic vaccine in the clinic and a telomerase inhibitor at late stage of preclinical validation. We recently demonstrated that the adoptive transfer of T cell transduced with an HLA-A2-restricted T-cell receptor (TCR), which recognize human TERT with high avidity, controls human B-cell chronic lymphocytic leukaemia (B-CLL) progression without severe side-effects in humanized mice. In the present report, we show the ability of our approach to limit the progression of more aggressive leukemic pathologies, such as acute myeloid leukaemia (AML) and B-cell acute lymphoblastic leukaemia (B-ALL). Together, our findings demonstrate that TERT-based adoptive cell therapy is a concrete platform of T cell-mediated immunotherapy for leukaemia treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.